6.75
+8.00%
Close of 5 Nov 2026, in CAD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Devonian Health Group
Its shares trade on TSX Venture under the ticker GSD.V. It has been listed since 9 September 2014. In the fiscal year to 31 July 2025, it reported revenue of C$23.6m and a net loss of C$6.0m. At that date it held total assets of C$15.8m and shareholders' equity of C$9.1m.
Devonian Health Group, Inc. is a pharmaceutical company, which engages in the development of botanical drugs. The company is headquartered in Montmagny, Quebec. The company went IPO on 2014-09-09. The firm's main activity is the development of botanical drugs from plant materials and algae for the treatment of inflammatory-autoimmune diseases, including ulcerative colitis and atopic dermatitis. The company is also involved in the development of value-added products for dermo-cosmetics and the distribution of pharmaceutical products through its subsidiary. The Company’s flagship product, Thykamine, the pharmaceutical product issued from its SUPREX platform, is a product for the prevention and treatment of health conditions related to inflammation and oxidative stress. The Company’s flagship product, Thykamine, the pharmaceutical product issued from its SUPREX platform, is a product for the prevention and treatment of health conditions related to inflammation and oxidative stress. The firm's cosmeceutical products include R-Spinasome and Purgenesis.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 9 Sept 2014
- Employees
- 6
- Website
- groupedevonian.com ↗
Leadership
Pay as last reported
- Dr. Andre BouletChairman of the Board, Chief Operating Officer, Chief Scientific OfficerC$482,989
- Mr. Luc GregoirePresident, Chief Executive Officer, Director, since 2023C$395,538
- Mrs. Colette LaurinInterim Chief Financial Officer, ControllerC$259,565
- Mr. Pierre MontanaroPresident of Altius, since 2022C$346,354
- Mr. Erick ShieldsChief Commercial Officer of Altius Heatlcare Inc, since 2021
- Mr. David BakerIndependent DirectorC$41,380
- Mr. Edward DahlIndependent Director
- Dr. Louis FlamandIndependent Director
- Mr. Jean ForcioneIndependent Director
- Ms. Kathryn GregoryIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Devonian Health Group develops botanical drugs from plant materials and algae for inflammatory-autoimmune diseases.
- Thykamine, the flagship product from SUPREX platform, treats inflammation and oxidative stress conditions.
- R-Spinasome and Purgenesis are key cosmeceutical products in dermo-cosmetics segment.
Weaknesses
- Devonian Health Group has only 6 full-time employees, limiting operational capacity.
- The company's IPO on 9 September 2014 indicates limited market presence.
- Montmagny, Quebec, is a small city with minimal pharmaceutical industry infrastructure.
Opportunities
- The growing market for botanical drugs in Health Care sector offers expansion potential.
- Increasing demand for dermo-cosmetics products like R-Spinasome and Purgenesis presents growth opportunities.
- Development of value-added products for dermo-cosmetics can attract new customers.
Threats
- Competition in the pharmaceutical industry may impact Devonian Health Group's market share.
- Regulatory challenges in the Health Care sector could delay product approvals.
- The small employee count of 6 may hinder rapid response to market changes.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.